General Announcement::Glenmarks subsidiary,lchnos Sciences and Almirall enter into an exclusive Licensing Agreement

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
14-Dec-2021 18:25:46
Status
New
Announcement Sub Title
Glenmarks subsidiary,lchnos Sciences and Almirall enter into an exclusive Licensing Agreement
Announcement Reference
SG211214OTHRMQSL
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Ltd.
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
14/12/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark's subsidiary, lchnos Sciences and Almirall enter into an exclusive Licensing Agreement for First-In-Class IL-1RAP Antagonist Monoclonal Antibody

Attachments

SGX_PR_14122021.pdf
Total size =433K